DE4393381T1 - Peptide - Google Patents

Peptide

Info

Publication number
DE4393381T1
DE4393381T1 DE4393381T DE4393381T DE4393381T1 DE 4393381 T1 DE4393381 T1 DE 4393381T1 DE 4393381 T DE4393381 T DE 4393381T DE 4393381 T DE4393381 T DE 4393381T DE 4393381 T1 DE4393381 T1 DE 4393381T1
Authority
DE
Germany
Prior art keywords
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE4393381T
Other languages
English (en)
Other versions
DE4393381B4 (de
Inventor
Wilfried Bauer
Robin Dr Breckenridge
Francois Dr Cardinaux
Frank Dr Gombert
Hermann Dr Gram
Paul Dr Ramage
Helmut Dr Schneider
Rudolf Dr Waelchli
Rainer Dr Albert
Ian Dr Lewis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Sandoz AG
Sandoz Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929215009A external-priority patent/GB9215009D0/en
Priority claimed from GB929226415A external-priority patent/GB9226415D0/en
Priority claimed from GB929226859A external-priority patent/GB9226859D0/en
Priority claimed from GB929226861A external-priority patent/GB9226861D0/en
Priority claimed from GB939301691A external-priority patent/GB9301691D0/en
Priority claimed from GB939301692A external-priority patent/GB9301692D0/en
Priority claimed from GB939307673A external-priority patent/GB9307673D0/en
Priority claimed from GB939308033A external-priority patent/GB9308033D0/en
Application filed by Sandoz AG, Sandoz Patent GmbH filed Critical Sandoz AG
Publication of DE4393381T1 publication Critical patent/DE4393381T1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE4393381T 1992-07-15 1993-07-06 Peptide Withdrawn DE4393381T1 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB929215009A GB9215009D0 (en) 1992-07-15 1992-07-15 Organic compounds
GB929226415A GB9226415D0 (en) 1992-12-18 1992-12-18 Organic compounds
GB929226859A GB9226859D0 (en) 1992-12-23 1992-12-23 Organic compounds
GB929226861A GB9226861D0 (en) 1992-12-23 1992-12-23 Organic compounds
GB939301691A GB9301691D0 (en) 1993-01-28 1993-01-28 Organic compounds
GB939301692A GB9301692D0 (en) 1993-01-28 1993-01-28 Organic compounds
GB939307673A GB9307673D0 (en) 1993-04-14 1993-04-14 Organic compounds
GB939308033A GB9308033D0 (en) 1993-04-19 1993-04-19 Organic compounds
PCT/EP1993/001749 WO1994002510A2 (en) 1992-07-15 1993-07-06 Analogs of pth

Publications (1)

Publication Number Publication Date
DE4393381T1 true DE4393381T1 (de) 1995-04-27

Family

ID=27571302

Family Applications (2)

Application Number Title Priority Date Filing Date
DE4393381A Expired - Lifetime DE4393381B4 (de) 1992-07-15 1993-07-06 PTH-Verbindungen mit PTH-ähnlicher Aktivität, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Zusammensetzungen und deren Verwendungen
DE4393381T Withdrawn DE4393381T1 (de) 1992-07-15 1993-07-06 Peptide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE4393381A Expired - Lifetime DE4393381B4 (de) 1992-07-15 1993-07-06 PTH-Verbindungen mit PTH-ähnlicher Aktivität, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Zusammensetzungen und deren Verwendungen

Country Status (25)

Country Link
US (2) US20050009147A1 (de)
EP (1) EP0672057B1 (de)
JP (1) JP3164463B2 (de)
KR (1) KR100321651B1 (de)
CN (1) CN1051769C (de)
AT (1) AT408100B (de)
AU (1) AU672790B2 (de)
CA (1) CA2100423C (de)
CH (1) CH688195A5 (de)
CZ (1) CZ286889B6 (de)
DE (2) DE4393381B4 (de)
DK (1) DK0672057T3 (de)
ES (1) ES2150948T3 (de)
FI (1) FI113872B (de)
GB (1) GB2269176B (de)
GR (1) GR3035089T3 (de)
HK (1) HK1004896A1 (de)
HU (2) HUT70459A (de)
IL (1) IL106326A (de)
NO (1) NO319448B1 (de)
NZ (1) NZ248137A (de)
PT (1) PT672057E (de)
SG (1) SG63625A1 (de)
SK (1) SK283485B6 (de)
WO (1) WO1994002510A2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814603A (en) * 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
WO1995011697A1 (fr) * 1993-10-27 1995-05-04 Chugai Seiyaku Kabushiki Kaisha Accelerateur de guerison utilise en chondroplastie
US5955425A (en) * 1996-08-02 1999-09-21 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US6110892A (en) 1994-06-20 2000-08-29 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US5556940A (en) * 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
CO4410206A1 (es) * 1994-07-28 1997-01-09 Sandoz Ag DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
CA2178894A1 (en) * 1995-06-15 1996-12-16 Tsunehiko Fukuda Parathyroid hormone derivatives and their use
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5969095A (en) * 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5723577A (en) * 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
EP1352912A1 (de) * 1996-08-02 2003-10-15 National Research Council Of Canada Analoge des Parathormons zur Behandlung der Osteoporose
EE9900039A (et) * 1996-08-02 1999-08-16 National Research Council Of Canada Paratüreoidhormooni analoogid osteoporoosi raviks
BR9808786A (pt) 1997-05-14 2000-07-11 Rhone Poulenc Rorer Pharma Composto peptìdio cìclico ou um seu sal ou pró-medicamento farmaceuticamente aceitáveis, composição farmacêutica, e, processos para tratar doenças associadas com a regulagem do cálcio em um paciente e para tratar a osteopenia ou a osteoporose em um mamìfero hospedeiro
EP1721617A3 (de) * 1997-07-22 2008-05-28 Chugai Seiyaku Kabushiki Kaisha Zahnärztliche Therapeutika enthaltend Parathyroidhormon
ES2244090T3 (es) * 1997-09-09 2005-12-01 F. Hoffmann-La Roche Ag Curacion de fracturas utilizando analogos de pthrp.
EP1075491B1 (de) 1998-05-05 2008-04-16 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Pth2 rezeptor selektive verbindungen
WO2000023594A1 (en) 1998-10-22 2000-04-27 The General Hospital Corporation BIOACTIVE PEPTIDES AND PEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHrP)
JP4486258B2 (ja) 1998-11-25 2010-06-23 ザ・ジェネラル・ホスピタル・コーポレイション ヒト副甲状腺ホルモンの改変、調製および使用
EP1147133B1 (de) * 1998-12-31 2008-08-06 The General Hospital Corporation Peptide, bestehend aus zwei funktionellen PTH-Domänen, die durch ein Linkermolekül verknüpft sind, und Derivate davon
US7057012B1 (en) 1998-12-31 2006-06-06 The General Hospital Corporation PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
EP1141237B1 (de) 1998-12-31 2005-11-02 The General Hospital Corporation Pth rezeptor und testverfahren unter verwendung desselben
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
DE19916419B4 (de) * 1999-04-08 2005-06-16 Schering Ag Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
AU7734800A (en) 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
EP1439854B1 (de) 2001-07-23 2016-12-14 The General Hospital Corporation Parathormon (pth)-analoga mit beschränkter konformation
JP2005525312A (ja) 2002-01-10 2005-08-25 オステオトロフィン エルエルシー 骨同化物質を用いた骨疾患の治療方法
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7906480B2 (en) 2002-05-23 2011-03-15 Michael Holick Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
AU2002951372A0 (en) * 2002-09-13 2002-09-26 St Vincent's Institute Of Medical Research Parathyroid hormone-like polypeptides
US7795220B2 (en) 2003-03-19 2010-09-14 The General Hospital Corporation Conformationally constrained parathyroid hormones with alpha-helix stabilizers
WO2005009358A2 (en) 2003-07-17 2005-02-03 The General Hospital Corporation Conformationally constrained parathyroid hormone (pth) analogs
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
EP1744683B1 (de) 2004-05-13 2016-03-16 Alza Corporation Gerät und verfahren für die transdermale abgabe von parathyroidhormon-mitteln
US9052324B2 (en) 2004-05-19 2015-06-09 Enzo Biochem, Inc. Compounds and assays for controlling Wnt activity
KR20070115947A (ko) 2005-02-11 2007-12-06 아밀린 파마슈티칼스, 인크. 선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
WO2007028632A2 (en) * 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
WO2007028633A2 (en) * 2005-09-08 2007-03-15 Uutech Limited Treatment of diabetes related obesity
AU2006315132A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
EP2054077A4 (de) * 2006-08-04 2010-10-13 Gen Hospital Corp Polypeptidderivate des parathyroidhormons (pth)
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
EP2084183B1 (de) 2006-10-13 2010-05-26 Eli Lilly & Company Pegyliertes pth als pth-rezeptormodulatoren und ihre verwendung
CA3017668C (en) 2007-08-01 2021-11-09 The General Hospital Corporation Screening methods using g-protein coupled receptors and related compositions
CA2740873C (en) 2008-10-17 2019-09-10 Wisconsin Alumni Research Foundation Method of making biologically active alpha-beta peptides
CN102448482A (zh) 2009-03-27 2012-05-09 范安德尔研究所 甲状旁腺素肽和甲状旁腺素相关蛋白肽及使用方法
EP2509996A1 (de) 2009-12-07 2012-10-17 Michigan Technological University Schwarzbär-parathyroid-hormon und verfahren zur verwendung des schwarzbär-parathyroid-hormons
MX358161B (es) 2010-05-13 2018-08-06 The General Hospital Corp Star Analogos de hormona paratiroidea y usos para los mismos.
US8609621B2 (en) 2010-11-15 2013-12-17 E I Du Pont De Nemours And Company Acid-cleavable linkers exhibiting altered rates of acid hydrolysis
JP2014508765A (ja) * 2011-03-01 2014-04-10 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 副甲状腺ホルモン類似体、組成物およびその使用
US20170037086A1 (en) * 2014-04-09 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with pth activity
JP2022511515A (ja) 2018-12-20 2022-01-31 ケーエスキュー セラピューティクス， インコーポレイテッド 置換されたピラゾロピリミジン及び置換されたプリンならびにユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤としてのそれらの使用
CN116615424A (zh) 2020-10-30 2023-08-18 Ksq治疗公司 经取代的吡唑并嘧啶的固态形式和其用途
WO2023066881A1 (en) 2021-10-18 2023-04-27 Astrazeneca Ab Inhibition of map3k15 for treating and preventing diabetes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886132A (en) * 1972-12-21 1975-05-27 Us Health Human parathyroid hormone
US4423037A (en) * 1982-05-13 1983-12-27 The General Hospital Corporation Inhibitors of peptide hormone action
FR2550204B1 (fr) * 1983-08-05 1987-11-13 Toyo Jozo Kk Derives peptidiques de (nle8,nle1b, tyr34)-h-pth
US4752585A (en) * 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
US5420242A (en) * 1986-10-22 1995-05-30 Kaare M. Gautvik Production of human parathyroid hormone from microorganisms
US4771124A (en) * 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology
EP0293158A3 (de) * 1987-05-26 1990-05-09 Merck & Co. Inc. Parathyroide Hormon-Antagonisten
US5001223A (en) * 1987-05-26 1991-03-19 Merck & Co., Inc. Parathyroid hormone antagonists with enhanced metabolic properties
DE3725320A1 (de) * 1987-07-30 1989-02-09 Biotechnolog Forschung Gmbh Expressionsvektoren und verfahren unter deren verwendung zur gewinnung von cro/ss-galaktosidase/pth-fusionsproteinen und von pth
US4968669A (en) * 1988-05-09 1990-11-06 Merck & Co., Inc. Parathyroid hormone antagonists
JPH03504201A (ja) * 1989-02-23 1991-09-19 ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング　（ゲー・ベー・エフ） Ｐｔｈ変種をコードするｄｎａ配列、ｐｔｈ変種、発現ベクター、細菌宿主、利用と治療用組成物
CA2040264A1 (en) * 1990-04-12 1991-10-13 Tatsuhiko Kanmera Parathyroid hormone antagonists
US5093233A (en) * 1990-04-25 1992-03-03 Merck & Co., Inc. Antagonists with position 13 modification
GB9020544D0 (en) * 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
JPH0532696A (ja) * 1990-09-28 1993-02-09 Takeda Chem Ind Ltd 副甲状腺ホルモン誘導体
AU9103791A (en) * 1990-12-21 1992-07-22 Allelix Biopharmaceuticals Inc. Oxidation resistant variants of parathyroid hormone
ES2087323T3 (es) * 1991-02-19 1996-07-16 Takeda Chemical Industries Ltd Metodo para producir peptidos exentos de cisteina.
US5317010A (en) * 1991-10-10 1994-05-31 Peter K. T. Pang Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment
US5434246A (en) * 1992-03-19 1995-07-18 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives
US5382658A (en) * 1992-04-03 1995-01-17 Allelix Biopharmaceuticals Inc. Stability-enhanced variants of parathyroid hormone
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis

Also Published As

Publication number Publication date
EP0672057A1 (de) 1995-09-20
CH688195A5 (de) 1997-06-13
CZ8895A3 (en) 1995-10-18
DE4393381B4 (de) 2008-07-17
SK4395A3 (en) 1995-06-07
GB2269176B (en) 1997-01-08
GB2269176A (en) 1994-02-02
NO950123L (no) 1995-03-15
IL106326A (en) 1997-09-30
CN1099801A (zh) 1995-03-08
JPH06184198A (ja) 1994-07-05
FI950171A0 (fi) 1995-01-13
HUT70459A (en) 1995-10-30
SG63625A1 (en) 1999-03-30
JP3164463B2 (ja) 2001-05-08
US20050009147A1 (en) 2005-01-13
GR3035089T3 (en) 2001-03-30
NO950123D0 (no) 1995-01-12
CZ286889B6 (en) 2000-07-12
CA2100423C (en) 2005-06-14
ES2150948T3 (es) 2000-12-16
PT672057E (pt) 2001-02-28
AU672790B2 (en) 1996-10-17
KR100321651B1 (ko) 2002-05-13
HU211856A9 (en) 1995-12-28
FI950171A (fi) 1995-03-13
ATA903993A (de) 2001-01-15
CA2100423A1 (en) 1994-01-16
NZ248137A (en) 1995-12-21
KR940005670A (ko) 1994-03-22
SK283485B6 (sk) 2003-08-05
WO1994002510A3 (en) 1994-05-26
DK0672057T3 (da) 2000-12-27
WO1994002510A2 (en) 1994-02-03
AU4156693A (en) 1994-01-20
CN1051769C (zh) 2000-04-26
US20080318838A1 (en) 2008-12-25
HK1004896A1 (en) 1998-12-11
EP0672057B1 (de) 2000-09-20
IL106326A0 (en) 1994-04-12
FI113872B (fi) 2004-06-30
NO319448B1 (no) 2005-08-15
AT408100B (de) 2001-08-27
GB9314384D0 (en) 1993-08-25
HU9500115D0 (en) 1995-03-28

Similar Documents

Publication Publication Date Title
DE4393381T1 (de) Peptide
DE69332485D1 (de) Immunmodulierende peptide
DE69129395D1 (de) Antimikrobielle Peptide
DE69315842D1 (de) Peptidverbindungen
NO942066L (no) Peptidderivater
DK6893D0 (da) Peptid
IS4115A (is) Ný peptíð
FI940109A (fi) Peptidejä
FI970168A (fi) Peptidejä
DE69427363T2 (de) Plättchenaggregationsinhibierende peptide
NO943540D0 (no) Antivirale peptider
BR9606756A (pt) Peptídeo
DE69314120T2 (de) Phospholipase c hemmendes peptid
NO981052D0 (no) Peptidderivater
NO932237D0 (no) Lineaere peptider
MA22717A1 (fr) Peptides hemoregulateurs
NO981051D0 (no) Peptidderivater
NO177858C (no) Peptid
LV10286A (lv) Peptidu savienojumi
DE69638206D1 (de) Antineoplastische Peptide
DE69420044D1 (de) Blutregulierende peptide
LV10287A (lv) Peptidu savienojumi
DE68914057D1 (de) Peptide.
ITMI922963A0 (it) Peptidi ciclici
SE9504467D0 (sv) Peptide

Legal Events

Date Code Title Description
8127 New person/name/address of the applicant

Owner name: NOVARTIS AG, BASEL, CH

8110 Request for examination paragraph 44
8125 Change of the main classification

Ipc: C07K 14/635

8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8339 Ceased/non-payment of the annual fee
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Effective date: 20110201

R082 Change of representative

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN, DE

Representative=s name: DR. SCHOEN & PARTNER, DE

Representative=s name: DR. SCHOEN, NEYMEYR & PARTNER MBB, DE